0R3M Stock Overview
A clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Vivoryon Therapeutics N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.11 |
| 52 Week High | €9.74 |
| 52 Week Low | €0.41 |
| Beta | 1.99 |
| 11 Month Change | -11.53% |
| 3 Month Change | -7.05% |
| 1 Year Change | -73.73% |
| 33 Year Change | -88.71% |
| 5 Year Change | -62.39% |
| Change since IPO | -88.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0R3M | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 1.4% | -6.0% | -0.3% |
| 1Y | -73.7% | -22.4% | 6.1% |
Return vs Industry: 0R3M underperformed the UK Biotechs industry which returned -22.4% over the past year.
Return vs Market: 0R3M underperformed the UK Market which returned 6.1% over the past year.
Price Volatility
| 0R3M volatility | |
|---|---|
| 0R3M Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0R3M's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0R3M's weekly volatility has decreased from 27% to 11% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 15 | Frank Weber | www.vivoryon.com |
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease.
Vivoryon Therapeutics N.V. Fundamentals Summary
| 0R3M fundamental statistics | |
|---|---|
| Market cap | €54.35m |
| Earnings (TTM) | -€31.18m |
| Revenue (TTM) | n/a |
-15.0x
P/S Ratio-1.7x
P/E RatioIs 0R3M overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0R3M income statement (TTM) | |
|---|---|
| Revenue | -€3.62m |
| Cost of Revenue | -€525.00k |
| Gross Profit | -€3.09m |
| Other Expenses | €28.09m |
| Earnings | -€31.18m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.20 |
| Gross Margin | 85.50% |
| Net Profit Margin | 861.46% |
| Debt/Equity Ratio | 0% |
How did 0R3M perform over the long term?
See historical performance and comparison